Welcome to our dedicated page for Keros Therapeutics news (Ticker: KROS), a resource for investors and traders seeking the latest updates and insights on Keros Therapeutics stock.
Keros Therapeutics, Inc. (Nasdaq: KROS) is a clinical-stage biopharmaceutical company whose news flow centers on its TGF-ß pathway–focused pipeline, corporate strategy and capital allocation decisions. The company’s disclosures describe a focus on developing protein therapeutics for disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins, with particular emphasis on neuromuscular and hematologic conditions.
News about Keros frequently highlights clinical development milestones for its lead product candidate, KER-065, which is being developed for neuromuscular diseases with an initial focus on Duchenne muscular dystrophy. Recent updates have included Phase 1 clinical data in healthy volunteers, additional analyses of bone and muscle-related endpoints, and U.S. Food and Drug Administration Orphan Drug designation for KER-065 in DMD. Investors following KROS news can expect coverage of trial design, safety and pharmacodynamic findings, and plans for subsequent clinical phases.
Another recurring theme in Keros news is progress related to elritercept, the company’s most advanced product candidate for cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndrome and myelofibrosis. The company has reported developments under its global license agreement with Takeda Pharmaceuticals U.S.A., Inc., including Takeda’s plans to advance elritercept into a Phase 3 clinical trial in first-line myelodysplastic syndromes.
Keros’ news flow also includes corporate and financial updates. These have covered a strategic realignment to prioritize KER-065, discontinuation of internal development of cibotercept (KER-012), leadership and board changes, and a substantial capital return program involving stock repurchase agreements and a cash tender offer for a significant portion of its outstanding common stock. Earnings releases and Form 8-K filings provide additional context on financial results, cash position and the execution of the capital return plan.
For investors and observers, the KROS news page offers a consolidated view of clinical trial announcements, regulatory designations, partnership developments, governance changes and capital allocation actions that shape the company’s trajectory. Regular review of these updates can help track how Keros advances its TGF-ß–focused pipeline and manages its resources over time.
Keros Therapeutics (Nasdaq: KROS), a clinical-stage biopharmaceutical company, announced participation in a fireside chat at the SVB Securities Global Biopharma Conference on February 14, 2023, at 3:40 p.m. ET. President and CEO Jasbir S. Seehra, Ph.D., will represent the company.
A live audio webcast of the event will be available here, with an archived replay accessible on Keros' website for up to 90 days post-event. Keros focuses on novel treatments for hematological, pulmonary, and cardiovascular disorders, including lead candidates KER-050, KER-047, and KER-012.
Keros Therapeutics presented new data from its ongoing Phase 2 clinical trials during the 2022 ASH Annual Meeting, focusing on KER-050 for myelodysplastic syndromes (MDS) and myelofibrosis (MF), and KER-047 for iron-refractory iron deficiency anemia (IRIDA). Results showed a 51.7% erythroid response rate in MDS patients receiving KER-050, with treatment well-tolerated and no serious adverse events reported. Initial data for KER-047 indicated potential iron redistribution. The company maintains a focus on developing treatments for hematological disorders with high unmet medical needs.
Keros Therapeutics, Inc. (Nasdaq: KROS), a clinical-stage biopharmaceutical company, announced that President and CEO Jasbir S. Seehra, Ph.D., will participate in upcoming fireside chats at the Piper Sandler 34th Annual Healthcare Conference and the 5th Annual Evercore ISI HealthCONx Conference.
Piper Sandler Conference: November 29, 10:00 a.m. ET. Live audio webcast available here.
Evercore ISI Conference: December 1, 8:50 a.m. ET. Live audio webcast available here.
Keros Therapeutics, Inc. (KROS) announced promising preclinical results for RKER-012, a novel treatment for pulmonary arterial hypertension (PAH). The findings, presented at the American Heart Association 2022 Scientific Sessions, show that RKER-012 improved cardiac and pulmonary function in a rat model of PAH. The treatment significantly reduced inflammatory and fibrotic markers, indicating potential for treating not just PAH but other inflammatory diseases. KER-012's development targets crucial pathways involved in fibrosis and cardiac hypertrophy.
Keros Therapeutics (KROS) announced the acceptance of five abstracts for presentation at the 64th American Society of Hematology Annual Meeting, scheduled for December 10-13, 2022. The presentations include preliminary results from Phase 2 trials for KER-050, aimed at treating myelodysplastic syndromes and myelofibrosis, and KER-047 for iron-refractory iron deficiency anemia. CEO Jasbir S. Seehra highlighted this as an opportunity to share important updates and anticipates releasing additional efficacy data for KER-050 by mid-December.
Keros Therapeutics (KROS) reported a net loss of $23.5 million for Q3 2022, up from $20.3 million in Q3 2021, primarily due to increased R&D efforts. The company spent $21.0 million on R&D, a rise of $6.2 million year-over-year, while general administrative expenses also increased to $6.9 million. As of September 30, 2022, Keros held $239.4 million in cash, bolstered by recent share sales, ensuring funding into Q1 2025. The company is advancing its clinical programs and anticipates a Phase 2 trial for KER-012 in pulmonary arterial hypertension, with more data expected by year-end.
Keros Therapeutics (KROS) announced preliminary clinical data from the Part 2 multiple ascending dose portion of its Phase 1 trial of KER-012, presented at the American Society of Bone and Mineral Research annual meeting on September 11, 2022. The results indicate that KER-012 effectively inhibits activin signaling, evidenced by a 52% reduction in follicle-stimulating hormone levels and significant increases in bone-specific alkaline phosphatase markers. No clinically meaningful changes were noted in hemoglobin or red blood cells. Keros plans to initiate a Phase 2 trial for KER-012 in pulmonary arterial hypertension patients in early 2023.
Keros Therapeutics, Inc. (Nasdaq: KROS) announced participation in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on September 12, 2022, at 3:40 PM ET. CEO Jasbir S. Seehra, Ph.D., and CFO Keith Regnante will discuss the company's innovative treatments aimed at hematological, pulmonary, and musculoskeletal disorders. A live audio webcast will be available, and an archived replay can be accessed for 90 days on Keros' website. Keros focuses on developing therapies like KER-050, KER-047, and KER-012 for various medical needs.
Keros Therapeutics (Nasdaq: KROS) announced two abstracts from its KER-012 and KER-050 programs will be presented at the ASBMR 2022 Annual Meeting in Austin, Texas, from September 9-12, 2022. The oral presentation on KER-012 will discuss its tolerability and its potential bone anabolic effects, scheduled for September 11, 2022. Additionally, a poster presentation on KER-050 will cover its efficacy in improving bone loss in a mouse model of myelodysplastic syndrome, also on September 11, 2022.
Keros Therapeutics reported positive clinical data for KER-050 and KER-012, showcasing their potential in treating hematological disorders. In the Phase 2 study for KER-050, 44% of high transfusion burden patients achieved transfusion independence. KER-012 demonstrated favorable safety and biomarker improvements in healthy volunteers. Keros strengthened its cash position, extending its runway to Q3 2024. However, the company reported a net loss of $27.3 million for Q2 2022, up from $15.6 million in Q2 2021, attributed to increased R&D and infrastructure costs.